Pazopanib

Generic Name: Pazopanib

Brand Names: Votrient

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₃N_₇O_₂S

CAS Number: 444731-52-6

Unique Ingredient Identifier: 7RN5DR86CK

Background: Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

Indication: Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)

Associated Conditions: Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer

Clinical Trials

Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Pazopanib
Drug: Paclitaxel

First Posted Date: 2015-03-09

Last Posted Date: 2023-09-06

Lead Sponsor: ARCAGY/ GINECO GROUP

Target Recruit Count: 118

Registration Number: NCT02383251

Locations: 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷
Hôpital Henri Duffaut, Avignon, France
🇫🇷
Centre Jean Perrin, Clermont-ferrand, France

and more 33 locations

Pazopanib for Treating Uterine Leiomyosarcoma

Phase 2

Withdrawn

Conditions: Uterine Leiomyosarcoma

Interventions: Drug: Pazopanib

First Posted Date: 2015-03-04

Last Posted Date: 2015-11-18

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT02378142

Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma

Phase 2

Withdrawn

Conditions: Sarcoma, Soft Tissue

Interventions: Drug: Pazopanib 800 mg
Drug: Placebo

First Posted Date: 2015-02-20

Last Posted Date: 2016-10-12

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT02367651

Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas

Phase 2

Completed

Conditions: Metastatic Osteosarcoma
Recurrent Liposarcoma
Recurrent Osteosarcoma
Stage IV Adult Soft Tissue Sarcoma
Adult Liposarcoma
Metastatic Liposarcoma
Recurrent Adult Soft Tissue Sarcoma

Interventions: Drug: Pazopanib Hydrochloride
Drug: Oral Topotecan Hydrochloride
Other: Laboratory Biomarker Analysis

First Posted Date: 2015-02-06

Last Posted Date: 2022-06-07

Lead Sponsor: Northwestern University

Target Recruit Count: 178

Registration Number: NCT02357810

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 5 locations

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

Conditions: Solid Tumors

First Posted Date: 2015-02-03

Last Posted Date: 2021-02-15

Lead Sponsor: Tracon Pharmaceuticals Inc.

Registration Number: NCT02354612

Locations: 🇺🇸
UCLA, Santa Monica, California, United States

Phase II Study of Pazopanib and Topotecan in Cervical Cancer

Phase 2

Withdrawn

Conditions: Cervical Cancer

Interventions: Drug: Pazopanib
Drug: Topotecan
Behavioral: Phone Call

First Posted Date: 2015-01-28

Last Posted Date: 2016-08-16

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT02348398

SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)

Phase 2

Withdrawn

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: Pazopanib
Drug: Trametinib

First Posted Date: 2015-01-21

Last Posted Date: 2017-10-12

Lead Sponsor: Sarcoma Alliance for Research through Collaboration

Registration Number: NCT02342600

Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 1

Recruiting

Conditions: Glioblastoma Multiforme

Interventions: Drug: Pazopanib

First Posted Date: 2015-01-06

Last Posted Date: 2025-05-20

Lead Sponsor: Centre Antoine Lacassagne

Target Recruit Count: 51

Registration Number: NCT02331498

Locations: 🇫🇷
Centre Antoine Lacassagne, Nice, Cedex 2, France

Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients

Phase 2

Conditions: Adverse Drug Event
Carcinoma, Renal Cell
Self Efficacy

Interventions: Drug: pazopanib

First Posted Date: 2014-12-24

Last Posted Date: 2014-12-24

Lead Sponsor: Southern China Urology Cancer Consortium

Target Recruit Count: 86

Registration Number: NCT02324803

Locations: 🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer

Not Applicable

Withdrawn

Conditions: Clear Cell Renal Cell Carcinoma
Renal Cell Carcinoma

Interventions: Radiation: Stereotactic Radiosurgery
Drug: Pazopanib Hydrochloride

First Posted Date: 2014-12-04

Last Posted Date: 2016-03-03

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT02307474

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy